Treatment of Candida Urinary Tract Infection with Urinary Retention

Introduction to Candiduria Treatment

• The Infectious Diseases Society of America recommends initiating antifungal therapy with oral fluconazole 200 mg daily for 2 weeks, and urgently addressing the urinary retention in patients with Candida urinary tract infection and urinary retention 1, 2

When to Treat Candiduria

• Antifungal therapy is indicated in patients with urinary symptoms and urinary retention, as the presence of symptoms distinguishes this from asymptomatic colonization, which typically does not require treatment 1, 2, 3
• Urinary retention represents obstruction, which is a strong indication for treatment regardless of symptom severity 2, 4

First-Line Antifungal Selection

• The American College of Clinical Pharmacology recommends fluconazole as the drug of choice for symptomatic Candida cystitis 1, 2, 5
• Oral fluconazole 200 mg daily for 2 weeks is the recommended dose for symptomatic cystitis 1, 2, 6, 7

Critical Management of Urinary Retention

• The European Association of Urology recommends elimination of urinary tract obstruction as a priority alongside antifungal therapy 2, 4
• Urinary retention must be addressed urgently, as obstruction precludes successful antifungal treatment alone 2, 5, 4

Alternative Agents for Resistant Species

• The Infectious Diseases Society of America recommends amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days for fluconazole-resistant C. glabrata 1, 2
• Oral flucytosine 25 mg/kg four times daily for 7-10 days can be used alone or with amphotericin B for fluconazole-resistant C. glabrata 1, 2, 3

Critical Pitfalls to Avoid

• The American College of Clinical Pharmacology recommends against using echinocandins or other azoles (besides fluconazole) for lower urinary tract Candida infections 2, 5, 4

Monitoring and Follow-Up

• The Infectious Diseases Society of America recommends assessing for disseminated candidiasis if the patient has additional risk factors, such as neutropenia or severe immunocompromise 3, 6, 7
• Current IDSA guidelines recommend 2 weeks of therapy for symptomatic Candida UTI 1, 2

Candida Urinary Tract Infections

Introduction to Candida UTIs

• Candida can cause urinary symptoms when it infects the urinary tract, though most cases of candiduria represent asymptomatic colonization rather than true infection, according to the Infectious Diseases Society of America 8, 9

Clinical Presentations

• Patients with symptomatic Candida urinary tract infection may experience cystitis symptoms, such as dysuria, urinary frequency, urgency, and suprapubic discomfort, as outlined by the Clinical Infectious Diseases guidelines 8, 9
• Pyelonephritis symptoms, including flank pain, fever, and systemic signs of infection, can also occur in patients with Candida urinary tract infection, as reported by the Clinical Infectious Diseases journal 8

Diagnosis and Treatment

• The presence of Candida in urine (candiduria) almost always represents colonization in asymptomatic patients, not true infection, according to the Clinical Infectious Diseases guidelines 9
• Treatment is indicated for symptomatic cystitis or pyelonephritis with documented Candida infection, as well as for high-risk asymptomatic patients, such as very low birth weight neonates, neutropenic patients, or patients undergoing urologic instrumentation, as recommended by the Infectious Diseases Society of America 9, 10
• Simply removing an indwelling catheter can eliminate candiduria in approximately 40-50% of asymptomatic patients without any antifungal therapy, as reported by the Clinical Infectious Diseases journal 10

Relationship to Vulvovaginal Candidiasis

• Vulvovaginal candidiasis (VVC) causes vaginal symptoms, including external dysuria, but this is not a true urinary tract infection, as distinguished by the Clinical Infectious Diseases guidelines 11
• VVC symptoms include pruritus, vaginal soreness, external dysuria, and dyspareunia with thick white discharge, as described by the Clinical Infectious Diseases journal 11

Diagnosis and Management of Yeast Cells with Hyphae in Urine

Species Identification and Treatment

• The Intensive Care Medicine society recommends differentiating C. albicans from other species using the germ-tube technique for non-sterile sites 12
• The Intensive Care Medicine society suggests obtaining species identification and susceptibility testing for persistent infection despite appropriate therapy 12

Diagnostic Testing for Urinary Candidiasis

Primary Diagnostic Approach

• Obtain a freshly voided urine sample for microscopy and culture; these remain the cornerstone diagnostic tests, and species identification is mandatory for all positive cultures. 13
• Urine microscopy can reveal yeasts and pseudohyphae, indicating possible fungal urinary infection, but this finding alone cannot differentiate infection from colonization. 13
• Culture on selective fungal media is essential to suppress bacterial overgrowth and confirm the presence of viable fungal organisms. 13
• Antifungal susceptibility testing should be performed for all isolates from symptomatic patients, especially in recurrent or complicated cases and after prior azole exposure. 13

Special Considerations for Catheterized Patients

• In patients with indwelling urinary catheters, standard urine culture yields > 50 % false‑negative results for biofilm‑associated infections. 14
• Despite the high false‑negative rate, freshly obtained bladder urine in catheterized patients should be processed with the same microscopy and culture methods as in non‑catheterized patients. 14
• Examination of removed catheters or stents is required for definitive detection of biofilm infection, although routine examination of every removed device is not recommended. 14

Imaging Studies

• Computed tomography (CT) imaging is superior to renal ultrasonography for detecting pyelonephritis or perinephric abscess in patients with suspected upper‑tract involvement. 15
• Imaging studies are not routinely indicated for uncomplicated cystitis; they should be obtained if symptoms persist beyond 72 hours or if upper‑tract involvement is suspected. 15

Molecular and Novel Diagnostics (Not Recommended)

• PCR‑based and other molecular diagnostic techniques cannot reliably distinguish true urinary Candida infection from asymptomatic colonization and lack clinical validation for this indication. 15
• Molecular tests also fail to assess organism viability or quantify burden, which are essential for differentiating colonization from infection, and may lead to overtreatment. 15